Analyst Tracker/Emmanuel Papadakis

Emmanuel Papadakis

Q: How accurate are Emmanuel Papadakis's stock ratings?

About 52% of Emmanuel's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, measured by 13Foresight from historical prices.

Q: How is Emmanuel ranked?

Emmanuel Papadakis is ranked #1537 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Deutsche Bank

Wall Street Analyst

★★★☆☆

#1537

on 13Foresight · ranked by our own returns

52%

Success Rate

+2.4%

Average Return

46 of 88 calls profitable · -2.2% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 52% of Emmanuel Papadakis's ratings turned a profit when each position was held for 1 year — averaging +2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

59 Buy 71 Hold 33 Sell

Emmanuel's Stock Coverage 34 ratings · 2026-11-03

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
GB:GSK GlaxoSmithKline	Oct 29, 2026	HOLD	Hold +5.2% avg upside 26 analysts	$2000.00 7.90% Upside	+2.3%	·
CH:ROP Roche Holding AG	Oct 28, 2026	BUY	Buy -12.1% avg upside 24 analysts	$500.00 23.96% Upside	+0.4%	·
GB:AZN AstraZeneca	Oct 28, 2026	HOLD	Strong Buy +7.8% avg upside 28 analysts	$11700.00 16.13% Downside	+9.4%	·
CH:NOVN Novartis AG	Oct 27, 2026	HOLD	Buy -15.0% avg upside 32 analysts	$120.00 10.27% Downside	+3.5%	·
GB:0QW0 arGEN X	Oct 23, 2026	HOLD	Strong Buy -23.5% avg upside 25 analysts	$850.00 5.65% Upside	·	·
GB:0QIU Novo Nordisk	Oct 07, 2026	SELL	Hold +52.9% avg upside 29 analysts	$225.00 13.59% Downside	·	·
FR:SAN Sanofi	Sep 29, 2026	BUY	Buy +21.3% avg upside 30 analysts	$95.00 19.14% Upside	+9.8%	·
GB:0MGB Genmab A/S	Sep 01, 2026	BUY	Buy -37.4% avg upside 25 analysts	$2500.00 34.40% Downside	·	·
BNTX BioNTech SE	Aug 26, 2026	BUY	Strong Buy +48.9% avg upside 28 analysts	$140.00 58.86% Upside	-22.2%	·
SE:SOBI Swedish Orphan Biovitrum AB	Jul 21, 2026	BUY	Strong Buy -7.1% avg upside 7 analysts	$515.00 4.98% Upside	+3.5%	·
ZLDPF Zealand Pharma	Jun 04, 2026	HOLD	Buy +137.6% avg upside 12 analysts	$44.96 35.84% Upside	-32.5%	·
CH:SDZ Sandoz Group Ltd	Apr 30, 2026	HOLD	Buy -14.9% avg upside 12 analysts	$65.00 21.05% Downside	+31.1%	·
NVO Novo Nordisk	Feb 23, 2026	HOLD	Hold +188.2% avg upside 26 analysts	—	+6.0%	·
GB:0NZT UCB SA	Dec 08, 2025	BUY	Buy -19.4% avg upside 19 analysts	$295.00 5.26% Upside	·	·
ARGX Argenx Se	Sep 11, 2025	HOLD	Strong Buy -8.2% avg upside 48 analysts	—	+28.9%	·
ES:GRF Grifols	Aug 05, 2025	HOLD	Buy +32.6% avg upside 13 analysts	$12.00 9.43% Upside	-19.5%	·
ES:ALM Almirall	Jul 28, 2025	BUY	Buy +25.3% avg upside 5 analysts	$14.00 32.07% Upside	+6.1%	·
NL:LKFT Lakefront Biotherapeutics NV	Apr 28, 2025	HOLD	Sell +75.8% avg upside 17 analysts	$22.00 23.96% Downside	+2.0%	·
SNY Sanofi	Jan 30, 2025	HOLD	Strong Buy +64.4% avg upside 20 analysts	—	-9.3%	·
CH:IDIA Idorsia Ltd	Nov 29, 2024	HOLD	Hold -4.8% avg upside 9 analysts	$1.00 77.71% Downside	+268.6%	·
MRNA Moderna	Aug 06, 2024	HOLD	Hold -48.5% avg upside 38 analysts	$80.00 63.85% Downside	-67.5%	·
LLY Eli Lilly & Co	Jul 17, 2024	HOLD	Strong Buy -16.7% avg upside 50 analysts	—	-15.3%	·
ALVO Alvotech	Jul 02, 2024	HOLD	Strong Buy +87.4% avg upside 7 analysts	$14.00 201.14% Upside	-27.0%	·
GRFS Grifols SA	Jun 18, 2024	HOLD	Buy +179.6% avg upside 13 analysts	—	+23.9%	·
FR:IPN Ipsen	Aug 07, 2023	HOLD	Hold -20.5% avg upside 17 analysts	$124.00 21.30% Downside	-14.6%	·
RHHBY Roche Holding	Jan 18, 2023	SELL	Strong Buy -14.6% avg upside 14 analysts	—	+7.5%	·
GMAB Genmab	Nov 11, 2022	HOLD	Buy +22.8% avg upside 28 analysts	—	-24.8%	·
IT:REC Recordati Industria Chimica e Farmaceutica SPA	Aug 09, 2022	HOLD	Buy -2.2% avg upside 9 analysts	$44.00 16.89% Downside	+9.3%	·
LKFT Lakefront Biotherapeutics	Aug 06, 2021	HOLD	Buy +217.3% avg upside 25 analysts	$56.00 73.40% Upside	-9.0%	·
GSK GlaxoSmithKline	Apr 16, 2021	SELL	Hold -14.7% avg upside 20 analysts	—	-29.4%	·
HK:0013 HUTCHMED (China)	Jul 15, 2020	HOLD	Buy +469.2% avg upside 6 analysts	—	·	·
DE:BAYN Bayer	Jul 14, 2020	BUY	Strong Buy +8.7% avg upside 31 analysts	$80.00 58.21% Upside	-18.1%	·
DE:MRK Merck KGaA	Jan 15, 2019	SELL	Buy -7.2% avg upside 34 analysts	$78.00 48.42% Downside	-28.4%	·
NVS Novartis	Dec 07, 2018	SELL	Hold -16.1% avg upside 24 analysts	—	-21.8%	·

🔒 29 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Emmanuel Papadakis — Frequently Asked Questions

How accurate are Emmanuel Papadakis's stock ratings?

Based on the calls 13Foresight could measure, about 52% of Emmanuel's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or -2.2% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Emmanuel ranked on 13Foresight?

Emmanuel Papadakis is currently ranked #1537 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Emmanuel cover?

Emmanuel most recently has ratings on GB:GSK, CH:ROP, GB:AZN, CH:NOVN, GB:0QW0, GB:0QIU, FR:SAN, GB:0MGB, BNTX, SE:SOBI, ZLDPF, CH:SDZ and 22 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Emmanuel Papadakis

Rating Distribution

Welcome to 13Foresight!